Zobrazeno 1 - 10 of 62 pro vyhledávání: '"Sue Cammarata"'
1
Akademický článek
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial
Autor: Sandra McCurdy, Ashley Nenninger, Amanda Sheets, Kara Keedy, Laura Lawrence, Megan Quintas, Sue Cammarata
Publikováno v: International Journal of Infectious Diseases, Vol 97, Iss , Pp 374-379 (2020)
Objectives: To report atypical pathogens from clinical trial data comparing delafloxacin to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP). Methods: Multiple diagnostic methods were employed to diagnose aty
Externí odkaz: https://doaj.org/article/8753cdbf01a943f1b490eb3d22e34b28
Zobrazit plný text záznamu
2
Akademický článek
A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections
Autor: William O’Riordan, Purvi Mehra, Paul Manos, Jeff Kingsley, Laura Lawrence, Sue Cammarata
Publikováno v: International Journal of Infectious Diseases, Vol 30, Iss C, Pp 67-73 (2015)
Background: A randomized, double-blind, multicenter trial was done to compare two doses of delafloxacin with tigecycline in patients with various complicated skin and skin-structure infections (wound infections following surgery, trauma, burns, or an
Externí odkaz: https://doaj.org/article/81d1298d84aa479ead489fe0bf5dd6c5
Zobrazit plný text záznamu
3
Efficacy and Safety of Single-Dose Oral Delafloxacin Compared With Intramuscular Ceftriaxone for Uncomplicated Gonorrhea Treatment: An Open-Label, Noninferiority, Phase 3, Multicenter, Randomized Study
Autor: Matthew R. Golden, Jerri Swerdlow, Edward W. Hook, Carol Tseng, Eugenia Henry, Kimberly A. Workowski, Ashley Nenninger, Stephanie N. Taylor, Sue Cammarata
Publikováno v: Sexually Transmitted Diseases. 46:279-286
We evaluated single oral dose of delafloxacin versus single intramuscular ceftriaxone in participants with uncomplicated urogenital gonorrhea (primary objective). Secondary objectives included the efficacy, safety, and tolerability of delafloxacin ve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77970c3a5c45e42b7977a18066629e24
https://doi.org/10.1097/olq.0000000000000971
Zobrazit plný text záznamu
4
Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
Autor: Jason M. Pogue, Sue Cammarata, Philip Giordano
Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Delafloxacin is an oral or intravenous (IV) antibiotic indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including both gram-positive (including methicillin-resistant Staphylococcus aureus [MRSA])
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::211e5ca22a245bdb319a2e3e81e24529
http://europepmc.org/articles/PMC6452004
Zobrazit plný text záznamu
5
Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial
Autor: Megan Quintas, Sandra P. McCurdy, Amanda Sheets, Kara Keedy, Laura Lawrence, Sue Cammarata, Ashley Nenninger
Publikováno v: International Journal of Infectious Diseases, Vol 97, Iss, Pp 374-379 (2020)
Objectives To report atypical pathogens from clinical trial data comparing delafloxacin to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP). Methods Multiple diagnostic methods were employed to diagnose atypi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196bcd9408ec6d90b58e16d14c583f44
https://pubmed.ncbi.nlm.nih.gov/32534142
Zobrazit plný text záznamu
6
Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
Autor: Megan Quintas, Sandra P. McCurdy, Amanda Sheets, Kara Keedy, Sue Cammarata, Laura Lawrence, Ashley Nenninger
Publikováno v: Antimicrobial Agents and Chemotherapy
Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative, and atypical pathogens, including fluoroquinolone-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA). The microbiological results of a phase 3
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5cda5e8ffcbb2fd305120224582c7cb
https://doi.org/10.1128/aac.01949-19
Zobrazit plný text záznamu
8
Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment
Autor: Randall Hoover, Harry Alcorn, Susan K. Paulson, Laura Lawrence, Sue Cammarata, David R. Luke, Megan Quintas
Publikováno v: Journal of Clinical Pharmacology
Delafloxacin, a fluoroquinolone, has activity against Gram‐positive organisms including methicillin‐resistant S aureus and fluoroquinolone‐susceptible and ‐resistant Gram‐negative organisms. The intravenous formulation of delafloxacin conta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a99deb11ec211c54fd535cbf51d44a
http://europepmc.org/articles/PMC6718009
Zobrazit plný text záznamu
9
Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
Autor: Harry Alcorn, Sue Cammarata, Laura Lawrence, Susan K. Paulson, Randall Hoover, Megan Quintas
Publikováno v: Journal of Clinical Pharmacology
Delafloxacin, a fluoroquinolone, has activity against gram‐positive organisms including methicillin‐resistant Staphylococcus aureus and fluoroquinolone‐susceptible and –resistant gram‐negative organisms. This study was conducted to determin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b24c1e1f587ddefaa213a6fbea92ac4
http://europepmc.org/articles/PMC5901045
Zobrazit plný text záznamu
10
Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study
Autor: R Ling, John Pullman, E Sun, J Gardovskis, Sue Cammarata, M Quintas, B Farley, Laura Lawrence
Publikováno v: Journal of Antimicrobial Chemotherapy
Background Delafloxacin is an investigational anionic fluoroquinolone in development for oral or intravenous administration for the treatment of infections caused by Gram-positive (including MRSA), Gram-negative, atypical and anaerobic organisms. Obj
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08c02cb16cb760a5f993caf093073e4d
https://doi.org/10.1093/jac/dkx329
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje